[Mycophenolate mofetil maintenance therapy in lupus nephritis].
The aim of this study was to assess clinical efficacy and changes in immunological parameters during maintenance therapy with mycophenolate mofetil (MMF) in patients with lupus nephritis. Patients (n = 7) with systemic lupus erythematosus (SLE) and proliferative nephropathy confirmed by renal biopsy, in whom disease remission was induced with intravenous cyclophosphamide, received MMF (2 x 500 mg daily) for 3 months. Clinical and immunological parameters as well as drug tolerance were assessed before, and after 1 and 3 months of MMF therapy. MMF therapy lead to a decrease in disease activity index (SLEDAI), and maintenance of previously achieved reduction of proteinuria, improvement of renal function and immunological parameters. These changes were associated with decrease in the number of activated T cells and increase in B cells. The titer of anti-dsDNA antibodies was reduced in 5 out of 7 patients. Mycofenolate mofetil is effective in the maintenance therapy oflupus nephritis. A 3-month MMF treatment allows for sustained beneficial immunological profile achieved in induction therapy.